Not Yet RecruitingNot Applicable

JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

7,150 participantsStarted 2025-08-25

Plain-language summary

The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Subjects with hypersensitivity or a history of hypersensitivity to the investigational drug or any of its components
✕. Subjects currently taking medications containing atazanavir, nelfinavir, or rilpivirine
✕. Pregnant women, women who may be pregnant, or breastfeeding women
✕. Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

What they're measuring

Change in Reflux Disease Questionnaire (RDQ) at Week 8

Timeframe: Week 8

Trial details

NCT IDNCT07115706

SponsorJeil Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-07-31

Contact for this trial

Minjeong Kim

+82 2-549-7451 mjkim1@jeilpharm.co.kr

View on ClinicalTrials.gov More Erosive Gastroesophageal Reflux Disease trials